Key clinical point: Landmark trial paves way to much wider use of LVADs as destination therapy.
Major finding: The 2-year rate of survival free of disabling stroke or reoperation to replace or remove a malfunctioning LVAD was 79.5% with the novel HeartMate 3 LVAD, compared with 60.2% with the commonly used HeartMate II axial-flow device.
Study details: This was a randomized, unblinded, multicenter study of more than 1,000 patients with advanced heart failure.
Disclosures: The MOMENTUM 3 trial was funded by Abbott. The presenter reported receiving research grants from and serving as a consultant to the company.
Source: Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.
Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.
This Week's Must Reads
Atovaquone associated with increased nocardiosis risk, Molina A et al. Acute Leukemia Forum 2018, Poster Session.
Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.
Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.
Venetoclax is effective in CLL that relapses after idelalisib, , Coutre S et al. Blood. 2018;131(15):1704-11
Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.
Must Reads in Thrombosis
2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103
VTE prophylaxis unaddressed in acutely ill patients, Amin A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 51.
Warfarin users take 10 other drugs on average, Jacobson A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018. Poster 2
LVADs as destination therapy, Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.
Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al